Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update

Aadi Bioscience, Inc. (NASDAQ:AADIGet Free Report) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 964,000 shares, a decline of 14.7% from the April 30th total of 1,130,000 shares. Based on an average daily volume of 331,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 5.5% of the shares of the stock are short sold.

Aadi Bioscience Price Performance

NASDAQ AADI opened at $1.74 on Friday. Aadi Bioscience has a 12 month low of $1.55 and a 12 month high of $8.49. The company has a market cap of $42.59 million, a P/E ratio of -0.68 and a beta of 0.64. The company has a 50-day moving average of $1.97 and a 200-day moving average of $2.44.

Aadi Bioscience (NASDAQ:AADIGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.02). The company had revenue of $5.35 million during the quarter, compared to analyst estimates of $6.41 million. Aadi Bioscience had a negative net margin of 288.72% and a negative return on equity of 61.83%. As a group, equities research analysts anticipate that Aadi Bioscience will post -2.54 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Aadi Bioscience in a report on Tuesday, May 14th.

Read Our Latest Research Report on Aadi Bioscience

Insider Activity at Aadi Bioscience

In other Aadi Bioscience news, Chairman Neil Desai sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $1.93, for a total transaction of $77,200.00. Following the sale, the chairman now directly owns 1,331,543 shares of the company’s stock, valued at approximately $2,569,877.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 72,736 shares of company stock valued at $149,678. 37.30% of the stock is owned by insiders.

Institutional Trading of Aadi Bioscience

An institutional investor recently bought a new position in Aadi Bioscience stock. Marquette Asset Management LLC purchased a new stake in Aadi Bioscience, Inc. (NASDAQ:AADIFree Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 57,807 shares of the company’s stock, valued at approximately $135,000. Marquette Asset Management LLC owned 0.24% of Aadi Bioscience as of its most recent filing with the SEC. Institutional investors own 52.08% of the company’s stock.

About Aadi Bioscience

(Get Free Report)

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

Featured Articles

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.